Key financial ranges
Market cap · USD equivalent
P/E ratio
Annual revenue · USD equivalent
Revenue growth
Valuation & profitability
Price / sales
Annual net income · USD equivalent
Net profit margin
Cash & debt
Cash · USD equivalent
Total debt · USD equivalent
Net cash · USD equivalent
Debt / revenue
| Company | Market cap | P/E | Revenue | Rev. growth | Net income | Cash | Debt | AI value |
|---|---|---|---|---|---|---|---|---|
| SAILSailPoint, Inc. | $10.98B | — | $1.07B | +24.4% | -$270.05M | $390.81M | $5.4M | Overvalued |
| RRXRegal Rexnord Corp | $10.97B | 33.9× | $5.93B | -1.6% | $279.5M | $441.6M | $4.86B | Fair valued |
| GNRCGenerac Holdings Inc. | $10.97B | 42.8× | $4.21B | -2.0% | $159.55M | $264.92M | $1.28B | Fair valued |
| UMBFUmb Financial Corp | $10.94B | 12.0× | $2.65B | +62.8% | $702.4M | $5.61B | $480.13M | Fair valued |
| BXPBXP, Inc. | $10.92B | 36.8× | $3.48B | +2.2% | $276.8M | $1.48B | $1.5B | Fair valued |
| ARWArrow Electronics, Inc. | $10.88B | 13.7× | $30.85B | +10.5% | $571.27M | $244.63M | $2.17B | Fair valued |
| NYTNew York Times Co | $10.87B | 28.1× | $2.82B | +9.2% | $343.98M | $232.66M | $48.72M | Fair valued |
| AXSMAxsome Therapeutics, Inc. | $10.87B | — | $638.5M | +65.5% | -$183.17M | $319.85M | $224.69M | Overvalued |
| OCOwens Corning | $10.85B | — | $10.1B | +2.6% | -$522M | $271M | $5.73B | Fair valued |
| ALSNAllison Transmission Holdings Inc | $10.8B | 20.8× | $3.01B | -6.7% | $623M | $399M | $4.22B | Fair valued |
| FDSFactset Research Systems Inc | $10.77B | 20.0× | $2.32B | +5.4% | $597.04M | $288.11M | $1.57B | Undervalued |
| EGPEastgroup Properties Inc | $10.75B | 35.1× | $721.34M | +12.7% | $257.46M | $33.38M | $1.62B | Fair valued |
| RYANRyan Specialty Holdings, Inc. | $10.73B | 61.6× | $2.99B | +21.9% | $63.4M | $140.12M | $3.81B | Overvalued |
| AMAntero Midstream Corp | $10.68B | 27.0× | $1.19B | +7.4% | $413.16M | $0 | $3.61B | Overvalued |
| GSATGlobalstar, Inc. | $10.65B | — | $272.99M | +9.0% | -$8.65M | $409.77M | $419.15M | Fair valued |
| KRYSKrystal Biotech, Inc. | $10.64B | 45.1× | $389.13M | +33.9% | $204.83M | $427.74M | $8.85M | Overvalued |
| LFUSLittelfuse Inc | $10.63B | — | $2.39B | +8.9% | -$71.7M | $481.7M | $700.65M | Overvalued |
| DCIDONALDSON Co INC | $10.58B | 23.7× | $3.69B | +2.9% | $367M | $204.1M | $601.9M | Fair valued |
| AESAes Corp | $10.56B | 5.5× | $12.23B | -0.4% | $910M | $1.8B | $1.17B | Fair valued |
| SANMSanmina Corp | $10.5B | 35.1× | $8.13B | +7.4% | $245.89M | $1.84B | $2.43B | Fair valued |